1. Home
  2. MOR

as 06-12-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.

Founded: 1992 Country:
Germany
Germany
Employees: N/A City: N/A
Market Cap: 2.8B IPO Year: 1999
Target Price: $12.13 AVG Volume (30 days): 393.2K
Analyst Decision: Hold Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.49 EPS Growth: N/A
52 Week Low/High: $4.19 - $19.50 Next Earning Date: 08-07-2024
Revenue: $264,753,681 Revenue Growth: -4.54%
Revenue Growth (this year): 3.95% Revenue Growth (next year): 19.04%

MOR Daily Stock ML Predictions

Share on Social Networks: